Hong Kong Luxury Stock News

Ascletis Pharma (SEHK:1672) has captured attention after sharing new Phase Ib data for its ASC30 oral tablet and injection. The results demonstrated up to 7% placebo-adjusted mean body weight reduction and strong safety signals, with only mild gastrointestinal issues reported. See our latest analysis for Ascletis Pharma. Ascletis Pharma’s rapid progress in its clinical obesity programs has sparked a flurry of investor enthusiasm, helping fuel a 243.5% year-to-date share price return. While...

Shandong Weigao Group Medical Polymer Company Limited announced on November 3, 2025, that unaudited third quarter revenue reached approximately RMB 3.26 billion, a 2.6% year-on-year increase. This steady revenue growth offers an up-to-date indicator of market demand for the company's medical device portfolio across China and beyond. We'll explore how this sustained sales momentum contributes to Shandong Weigao Group Medical Polymer's investment narrative and operational outlook. These 13...

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...

As global markets face fluctuations, with concerns about elevated valuations and economic uncertainties in major regions like the U.S. and Europe, Asia presents intriguing opportunities for investors seeking value. In this environment, identifying undervalued stocks—those trading below their intrinsic worth—can be a strategic approach to potentially benefit from market inefficiencies and capture future growth prospects.

Grand Pharmaceutical Group (HKG:512) has had a rough week with its share price down 3.1%. However, a closer look at its...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

China Silver Group's (HKG:815) stock is up by a considerable 40% over the past three months. We wonder if and what role...

With a median price-to-sales (or "P/S") ratio of close to 0.7x in the Luxury industry in Hong Kong, you could be...

Q Technology (Group) (SEHK:1478) reported a year-on-year rise in October 2025 sales volumes for its camera and fingerprint modules, reflecting gains in mobile phone, IoT, and smart vehicle markets. The company also exited its Q Tech India stake. See our latest analysis for Q Technology (Group). Q Technology’s latest operational gains have added a shot of energy to its momentum story this year. Despite recent volatility, with a 1-day share price climb of 4.34% offsetting some of last week’s...

Key Insights 361 Degrees International's estimated fair value is HK$7.57 based on 2 Stage Free Cash Flow to Equity 361...

Key Insights The considerable ownership by retail investors in Jiangsu Recbio Technology indicates that they...

Dongfeng Motor Group reported earnings for the nine months ended September 30, 2025, with sales reaching CNY 87,363.77 million and revenue at CNY 90,998.64 million, both up from the prior year, but net loss widening to CNY 1,881.82 million. This combination of rising revenue alongside a much larger net loss highlights ongoing operational challenges even as the company grows its top line. We'll explore how profit pressures amid sales growth are shaping Dongfeng Motor Group's investment...

Xinyi Glass Holdings Limited ( HKG:868 ), might not be a large cap stock, but it received a lot of attention from a...

Sunac Services Holdings (HKG:1516) has had a great run on the share market with its stock up by a significant 9.8% over...

Great China Holdings (Hong Kong) Limited ( HKG:21 ) shareholders should be happy to see the share price up 17% in the...

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. In a perfect...

Techtronic Industries Company Limited's ( HKG:669 ) price-to-earnings (or "P/E") ratio of 17.8x might make it look like...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Lepu Biopharma (SEHK:2157) just received conditional marketing approval from China's National Medical Products Administration for an innovative EGFR-targeted antibody-drug conjugate to treat recurrent or metastatic nasopharyngeal carcinoma. This milestone is expected to generate global attention and increased investor interest. See our latest analysis for Lepu Biopharma. Lepu Biopharma’s momentum has certainly kept investors on their toes this year. After surging to a 148% year-to-date share...

Key Insights The projected fair value for Beijing Tong Ren Tang Chinese Medicine is HK$11.42 based on 2 Stage Free Cash...

Green Economy Development Limited's ( HKG:1315 ) price-to-earnings (or "P/E") ratio of 5.2x might make it look like a...

With a median price-to-earnings (or "P/E") ratio of close to 13x in Hong Kong, you could be forgiven for feeling...

Some stocks are best avoided. We really hate to see fellow investors lose their hard-earned money. Spare a thought for...

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...